2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics
Key Takeaways
- The cell cycle is governed by sequential cyclin-dependent kinase (CDK) complexes; the G1/S restriction point transition is regulated by CDK4/6-cyclin D complexes phosphorylating the retinoblastoma protein (pRb), releasing E2F transcription factors to drive DNA replication.
- Tumor suppressor p53 (TP53), the 'guardian of the genome', is stabilized following DNA damage via ATM/ATR/CHK kinase cascades, transactivating p21Cip1 (CDKN1A) for cell cycle arrest or BAX/PUMA/NOXA to trigger apoptosis when damage exceeds repair capacity.
- The intrinsic apoptotic pathway is controlled by the balance of pro-survival (BCL-2, BCL-XL, MCL-1) and pro-apoptotic (BAX, BAK, BIM, PUMA) proteins; mitochondrial outer membrane permeabilization (MOMP) releases cytochrome c to form the heptameric apoptosome with APAF-1 and procaspase-9.
- Five major DNA damage repair (DDR) pathways maintain genomic integrity: Homologous Recombination (HR, error-free DSB repair via BRCA1/2, PALB2, RAD51), Non-Homologous End Joining (NHEJ, error-prone DSB repair via Ku70/80 and DNA-PKcs), Mismatch Repair (MMR via MLH1/MSH2/MSH6/PMS2), Base Excision Repair (BER via PARP1/2), and Nucleotide Excision Repair (NER via ERCC1-XPF).
- Synthetic lethality occurs when two non-lethal pathway defects combine to cause cell death; PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) trap PARP on single-strand breaks, causing replication fork collapse into double-strand breaks that HR-deficient (BRCA1/2-mutated or HRD+) cancer cells cannot repair.
Last updated: August 2026
2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics
Precision oncology therapeutics increasingly target the core biochemical machinery governing cellular replication, programmed cell death, and genomic maintenance. Mastery of cell cycle checkpoints, intrinsic/extrinsic apoptotic pathways, and the five major DNA repair pathways is foundational for understanding the mechanisms of cytotoxic chemotherapies, targeted cell cycle inhibitors, and synthetic lethal strategies.
1. Cell Cycle Kinetics & Phase-Specific Pharmacology
The eukaryotic cell cycle is a tightly ordered series of events dividing a single cell into two genetically identical daughter cells. Transitions between phases are strictly regulated by Cyclin-Dependent Kinases (CDKs), which are serine/threonine kinases activated upon binding to regulatory cyclin subunits.
+-----------------------------------------------------------------------------+
| THE EUKARYOTIC CELL CYCLE & DRUG TARGETS |
| |
| [ MITOSIS (M) ] |
| (Prophase -> Metaphase -> |
| Anaphase -> Telophase) |
| * TARGETS: Taxanes, Vincas, |
| Halichondrins (Eribulin) |
| ^ | |
| | v |
| [ G2 PHASE ] | [ G0 QUIESCENCE ] |
| (Pre-mitotic growth, | | |
| tubulin synthesis) | v |
| * TARGETS: Bleomycin, | [ G1 PHASE ] |
| Topoisomerase II | (RNA/protein synthesis, organelle |
| Inhibitors (Etoposide) | duplication) |
| | * TARGETS: CDK4/6 Inhibitors |
| | | |
| | v [ RESTRICTION POINT (R) ] |
| | | (pRb Phosphorylation / E2F) |
| | v |
| [ S PHASE (SYNTHESIS) ] |
| (DNA Replication) |
| * TARGETS: Antimetabolites (5-FU, MTX, |
| Gemcitabine, Cytarabine), Topo I (Irinotecan) |
| |
| * PHASE-NONSPECIFIC: Alkylating Agents (Cyclophosphamide, Ifosfamide), |
| Platinum Analogs (Cisplatin, Carboplatin), Anthracyclines (Doxorubicin) |
+-----------------------------------------------------------------------------+
Cell Cycle Phase, CDK Complexes & Chemotherapy Alignment
| Phase | Primary Cellular Function | Regulatory Cyclin-CDK Complex | Endogenous Inhibitors (CKIs) | Antineoplastic Drug Classes Acting in Phase |
|---|---|---|---|---|
| G0 | Quiescence / Resting state; non-cycling, metabolically active. | None. | High basal p27Kip1. | Phase-Nonspecific Agents: Alkylators, Nitrosoureas (active against resting cells, but cytotoxicity manifests when cells attempt division). |
| G1 | Cellular growth, RNA/protein synthesis; preparation for DNA replication. | Cyclin D + CDK4/CDK6<br>Cyclin E + CDK2 | INK4 Family: p16INK4a, p15, p18, p19.<br>Cip/Kip Family: p21Cip1/Waf1, p27Kip1, p57. | CDK4/6 Inhibitors: Palbociclib, Ribociclib, Abemaciclib (arrest cells at G1/S transition). |
| S | Semi-conservative DNA replication; histone synthesis. | Cyclin A + CDK2 | p21Cip1, p27Kip1. | Antimetabolites: 5-Fluorouracil, Capecitabine, Methotrexate, Pemetrexed, Cytarabine, Gemcitabine.<br>Topoisomerase I Inhibitors: Irinotecan, Topotecan. |
| G2 | Pre-mitotic proofreading; tubulin synthesis, organelle growth. | Cyclin A + CDK1<br>Cyclin B + CDK1 | Wee1 kinase (inhibitory phosphorylation), p21Cip1. | Topoisomerase II Inhibitors: Etoposide, Teniposide.<br>Antibiotics: Bleomycin (G2/M arrest via free-radical DNA scission). |
| M | Chromosome condensation, spindle alignment, sister chromatid segregation, cytokinesis. | Cyclin B + CDK1 (MPF: Maturation Promoting Factor) | Spindle Assembly Checkpoint (SAC): Mad2, BubR1 complex. | Microtubule Stabilizers: Taxanes (Paclitaxel, Docetaxel, Cabazitaxel), Epothilones (Ixabepilone).<br>Microtubule Destabilizers: Vinca Alkaloids (Vincristine, Vinblastine, Vinorelbine), Eribulin. |
2. Molecular Checkpoint Surveillance & The pRb / p53 Axes
Cell cycle fidelity is enforced by critical surveillance checkpoints that verify DNA integrity before allowing progression.
+-----------------------------------------------------------------------------+
| THE G1/S RESTRICTION POINT MOLECULAR AXIS |
| |
| Mitogenic Signals (Estrogen, Growth Factors, RTKs, RAS/MAPK) |
| | |
| v |
| [ UPREGULATE CYCLIN D ] |
| | |
| v |
| +---------------------------------------------------------------------+ |
| | [ ACTIVATED CDK4 / CDK6 COMPLEX ] | |
| +---------------------------------------------------------------------+ |
| | ^ |
| | (Phosphorylates) | (Inhibits) |
| v | |
| +-----------------------------+ +-------------------+ |
| | RETINOBLASTOMA (pRb) | | p16INK4a | |
| | HYPERPHOSPHORYLATION | | (CDKN2A Gene) | |
| +-----------------------------+ +-------------------+ |
| | ^ |
| v | (Inhibits) |
| [ RELEASE OF ACTIVE E2F TRANSCRIPTION FACTORS ] | |
| | +-------------------+ |
| v | CDK4/6 INHIBITORS| |
| [ TRANSCRIBE S-PHASE GENES ] | - Palbociclib | |
| (Cyclin E, Cyclin A, DNA Polymerase-alpha,| - Ribociclib | |
| Thymidine Kinase, PCNA) | - Abemaciclib | |
| | +-------------------+ |
| v |
| ==============================================> [ IRREVERSIBLE ENTRY |
| INTO S PHASE ] |
+-----------------------------------------------------------------------------+
The Retinoblastoma (pRb) Restriction Point Pathway
- In resting, uncommitted G1 cells, the hypophosphorylated retinoblastoma protein (pRb) binds tightly to E2F transcription factors, recruiting histone deacetylases (HDACs) to repress E2F-responsive promoters.
- Mitogenic signals induce Cyclin D synthesis, which pairs with CDK4 and CDK6 to initiate pRb mono-phosphorylation. Subsequently, Cyclin E-CDK2 hyperphosphorylates pRb, causing a conformational change that releases E2F.
- Free E2F transactivates genes required for DNA synthesis, committing the cell irreversibly to the cell cycle (the Restriction Point).
- Therapeutic Application: In Hormone Receptor-positive (HR+), HER2-negative metastatic breast cancer, hyperactive cyclin D-CDK4/6 signaling drives proliferation. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) block pRb phosphorylation, inducing durable G1 cell cycle arrest.
The p53 DNA Damage Response Axis
+-----------------------------------------------------------------------------+
| THE p53 DNA DAMAGE RESPONSE AXIS |
| |
| [ DNA DAMAGE: Double-Strand Breaks (DSBs) or Stalled Replication Forks ] |
| | |
| v |
| [ ATM / ATR SENSOR KINASE ACTIVATION ] |
| | |
| v |
| [ CHK2 / CHK1 TRANSDUCER KINASES ] |
| | |
| v (Phosphorylation of p53 at Ser15/Ser20) |
| +---------------------------------------------------------------------+ |
| | DISRUPTION OF MDM2 E3 UBIQUITIN LIGASE BINDING | |
| | ---> STABILIZATION & TETRAMERIZATION OF p53 | |
| +---------------------------------------------------------------------+ |
| | |
| +-----------------------+-----------------------+ |
| | (Mild / Repairable) | (Severe / Lethal) |
| v v |
| [ CELL CYCLE ARREST ] [ APOPTOSIS ] |
| - Transactivates CDKN1A (p21Cip1) - Transactivates BAX, |
| - p21 inhibits CDK2/CDK4 - Transactivates PUMA, |
| - G1/S and G2/M arrest - Transactivates NOXA |
| - Allows DDR enzymes to repair DNA - Triggers MOMP & Caspases|
+-----------------------------------------------------------------------------+
- Under physiological conditions, p53 protein levels are maintained at very low levels through continuous ubiquitination by the E3 ligase MDM2, which targets p53 for degradation by the 26S proteasome.
- Upon sensing DNA double-strand breaks (via ATM) or single-strand breaks / replication stress (via ATR), checkpoint kinases CHK2 and CHK1 phosphorylate p53 at Serine-15 and Serine-20. This blocks MDM2 binding, stabilizing p53.
- Stabilized p53 tetramers bind specific DNA response elements, functioning as a master transcription factor that transactivates:
CDKN1A(p21Cip1/Waf1): Broadly inhibits CDK4/6-Cyclin D and CDK2-Cyclin E, halting the cell cycle at G1/S to permit repair.GADD45: Facilitates DNA excision repair.BAX,BBC3(PUMA),PMAIP1(NOXA): Overwhelms anti-apoptotic BCL-2 defenses to trigger cell death when genomic damage is beyond repair.
3. Apoptosis Signaling Cascades (Programmed Cell Death)
Apoptosis is an energy-dependent, non-inflammatory programmed cell death mechanism characterized by cell shrinkage, membrane blebbing, chromatin condensation, and internucleosomal DNA cleavage.
+-----------------------------------------------------------------------------+
| INTRINSIC VS. EXTRINSIC APOPTOSIS SIGNALING DYNAMICS |
| |
| [ EXTRINSIC (DEATH RECEPTOR) PATHWAY ] [ INTRINSIC (MITOCHONDRIAL) ] |
| FASL, TNF-alpha, TRAIL DNA damage, Chemo, ROS, |
| | Oncogenic stress, Growth factor |
| v deprivation |
| Death Receptors (FAS/CD95, TNFR1, DR4/5) | |
| | (FADD Recruitment) v |
| v [ BH3-Only Proteins: |
| DISC Formation BIM, PUMA, NOXA, BID ] |
| | | | |
| v | v (Inhibits) |
| [ PRO-CASPASE-8 ACTIVATION ] | [ BCL-2, BCL-XL, |
| | | MCL-1 ] |
| +----------+ (tBID Cleavage) | |
| | | v (Direct Activation) |
| | +---------------------> [ BAX / BAK PORE FORMATION ] |
| | | |
| | v |
| | [ MOMP: Cytochrome c Release ] |
| | | |
| | v (+ APAF-1 + dATP) |
| | [ HEPTAMERIC APOPTOSOME ] |
| | | |
| | v |
| | [ PRO-CASPASE-9 ACTIVATION ] |
| | | |
| v v |
| +---------------------------------------------------------------------+ |
| | EXECUTIONER CASPASES (CASPASE-3, -7, -6) | |
| +---------------------------------------------------------------------+ |
| | |
| v |
| [ PROTEOLYSIS OF CRITICAL CELLULAR SUBSTRATES ] |
| - Cleavage of ICAD (Inhibitor of CAD) ---> CAD enters nucleus, |
| digests DNA into 180-200 bp nucleosomal fragments |
| - Cleavage of PARP1, Actin, Fodrin, Lamin (Nuclear Collapse) |
| - Externalization of Phosphatidylserine ---> Phagocytic uptake |
+-----------------------------------------------------------------------------+
The BCL-2 Protein Family Spectrum
| Functional Class | Key Family Members | Structural Domains | Biochemical Mechanism of Action |
|---|---|---|---|
| Anti-Apoptotic (Pro-Survival) | BCL-2, BCL-XL, MCL-1, BCL-W, BFL-1/A1 | BH1, BH2, BH3, BH4 (Multi-domain) | Sequester and neutralize pro-apoptotic effectors (BAX, BAK) and BH3-only activators (BIM), preventing mitochondrial pore formation. |
| Pro-Apoptotic Effectors (Pore-Formers) | BAX, BAK, BOK | BH1, BH2, BH3 (Multi-domain) | Upon activation, oligomerize within the mitochondrial outer membrane to create large macropores, executing Mitochondrial Outer Membrane Permeabilization (MOMP). |
| Pro-Apoptotic BH3-Only Activators | BIM, PUMA, tBID | BH3 domain only | Directly bind and trigger the allosteric conformational activation and oligomerization of BAX and BAK. |
| Pro-Apoptotic BH3-Only Sensitizers | BAD, NOXA, BIK, HRK | BH3 domain only | Competitively bind to anti-apoptotic proteins (e.g., BAD binds BCL-2/BCL-XL; NOXA binds MCL-1), displacing BIM/PUMA to activate BAX/BAK indirectly. |
Pharmacologic Targeting: Venetoclax
- Venetoclax is a first-in-class, highly selective oral BH3-mimetic that binds with high affinity (Ki < 0.01 nM) to the hydrophobic groove of BCL-2, mimicking native BH3-only sensitizers.
- Displaces pro-apoptotic proteins (BIM, BAX) from BCL-2 sequestration, permitting rapid, p53-independent BAX/BAK oligomerization, MOMP, cytochrome c release, and caspase-dependent apoptosis.
- Clinical Indications: Chronic lymphocytic leukemia (CLL/SLL) and acute myeloid leukemia (AML in combination with azacitidine, decitabine, or low-dose cytarabine).
- High-Stakes Toxicity: Rapid induction of massive apoptosis in high-bulk tumors causes severe Tumor Lysis Syndrome (TLS), necessitating strict 5-week dose ramp-up schedules and aggressive hydration/uric acid-lowering prophylaxis.
4. DNA Damage Repair (DDR) Pathways & Synthetic Lethality
Human cells experience thousands of DNA lesions daily from endogenous metabolic byproducts (ROS, depurination) and exogenous genotoxic insults (radiation, chemotherapeutic alkylators, platinums). Five distinct, non-redundant DNA repair pathways maintain genomic fidelity.
+-----------------------------------------------------------------------------+
| THE 5 CORE DNA DAMAGE REPAIR PATHWAYS |
| |
| [ BASE EXCISION REPAIR (BER) ] ---> Repairs single-strand breaks (SSBs), |
| oxidative base damage (8-oxoG). |
| * Enzymes: DNA Glycosylase, PARP1/2, |
| Pol-beta, Ligase III/XRCC1. |
| |
| [ NUCLEOTIDE EXCISION REPAIR (NER) ] -> Repairs bulky helix-distorting |
| lesions (cisplatin-DNA adducts, |
| UV pyrimidine dimers). |
| * Enzymes: XPA-XPG, ERCC1-XPF, TFIIH|
| |
| [ MISMATCH REPAIR (MMR) ] ---> Repairs base-base mismatches and small|
| insertion/deletion loops from repl. |
| * Enzymes: MSH2, MSH6, MLH1, PMS2. |
| |
| [ HOMOLOGOUS RECOMBINATION (HR) ] -> Error-free double-strand break (DSB) |
| repair during S/G2 phase (template). |
| * Enzymes: ATM, MRN, BRCA1, PALB2, |
| BRCA2, RAD51 nucleofilament. |
| |
| [ NON-HOMOLOGOUS END JOINING ] ---> Error-prone DSB repair across ALL |
| (NHEJ) phases (direct re-ligation). |
| * Enzymes: Ku70/80, DNA-PKcs, |
| Artemis, DNA Ligase IV/XRCC4. |
+-----------------------------------------------------------------------------+
Comprehensive DNA Repair Pathways Matrix
| Pathway | Target DNA Lesion Type | Key Enzymes & Repair Machinery | Primary Associated Malignancy / Syndromes | Clinical Pharmacologic Relevance |
|---|---|---|---|---|
| Base Excision Repair (BER) | Non-bulky base damage (oxidation, alkylation, deamination) and single-strand breaks (SSBs). | - DNA Glycosylases (OGG1, UNG).<br>- AP Endonuclease 1 (APE1).<br>- PARP1 & PARP2.<br>- DNA Polymerase beta, DNA Ligase III / XRCC1. | MUTYH-associated polyposis (MAP). | PARP Inhibitors: Olaparib, rucaparib, niraparib, talazoparib block BER, trapping PARP at SSBs. |
| Nucleotide Excision Repair (NER) | Bulky, helix-distorting intrastrand adducts, UV photoproducts, chemical crosslinks. | - Recognition: XPC, DDB1/2.<br>- Verification: XPA, RPA.<br>- Helicase unwinding: TFIIH complex (XPB, XPD).<br>- Dual Incision: ERCC1-XPF (5') and XPG (3').<br>- Resynthesis: Pol delta/epsilon, Ligase I. | Xeroderma Pigmentosum (XP). | Platinum Resistance: High tumor expression of ERCC1 correlates with rapid excision of cisplatin/carboplatin DNA crosslinks and clinical platinum resistance. |
| Mismatch Repair (MMR) | Base-base mismatches, insertion-deletion loops escaping DNA polymerase proofreading. | - Heterodimers: MutS-alpha (MSH2-MSH6) or MutS-beta (MSH2-MSH3).<br>- Endonuclease: MutL-alpha (MLH1-PMS2).<br>- Exonuclease 1 (EXO1), Pol delta, Ligase I. | - Lynch Syndrome (HNPCC).<br>- Sporadic MSI-H tumors via MLH1 promoter hypermethylation. | Immune Sensitivity: Defective MMR (dMMR/MSI-H) produces extreme neoantigen loads, conferring exquisite sensitivity to anti-PD-1 immunotherapy (pembrolizumab, dostarlimab). |
| Homologous Recombination (HR) | Double-strand breaks (DSBs), interstrand crosslinks (ICLs), collapsed replication forks. | - Sensor/Resection: MRN complex, ATM kinase, CtIP, EXO1.<br>- Mediators: BRCA1, PALB2, BRCA2.<br>- Recombinase: RAD51 nucleoprotein filament.<br>- Resolution: BCDX2, Holliday junction resolvases. | Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/2 germline mutations). | Synthetic Lethality: HR-deficient tumors (HRD+) cannot repair DSBs and exhibit extreme vulnerability to PARP inhibitors and platinum doublets. |
| Non-Homologous End Joining (NHEJ) | Double-strand breaks (DSBs) occurring in any phase (especially G0/G1 without sister chromatid). | - End Binding: Ku70 / Ku80 heterodimer.<br>- Kinase: DNA-PKcs.<br>- Processing: Artemis endonuclease.<br>- Ligation: DNA Ligase IV / XRCC4 / XLF complex. | Severe Combined Immunodeficiency (SCID with PRKDC or DCLRE1C mutations). | Error-prone; introduces random insertions/deletions (indels) leading to chromosomal translocations during radiotherapy and topoisomerase II poisoning. |
5. Synthetic Lethality & PARP Inhibitor Mechanics
The concept of synthetic lethality describes a genetic condition in which a defect in either of two genes/pathways alone preserves cell viability, but simultaneous deficiency in both pathways results in cell death.
+-----------------------------------------------------------------------------+
| MECHANISM OF SYNTHETIC LETHALITY WITH PARP INHIBITORS |
| |
| NORMAL CELL (BRCA1/2 Proficient) HRD CANCER CELL (BRCA1/2 Deficient)|
| ================================ ==================================|
| Endogenous Single-Strand Breaks (SSBs) Endogenous Single-Strand Breaks |
| | | |
| v v |
| [ + PARP INHIBITOR ] [ + PARP INHIBITOR ] |
| - Inhibits BER catalytic activity - Inhibits BER catalytic activity |
| - Traps PARP1 onto damaged DNA - Traps PARP1 onto damaged DNA |
| | | |
| v v |
| Replication forks collide with trapped Replication forks collide with |
| PARP ---> Double-Strand Breaks (DSBs) trapped PARP ---> DSBs |
| | | |
| v v |
| [ HOMOLOGOUS RECOMBINATION (HR) ] [ DEFECTIVE HOMOLOGOUS RECOMB. ] |
| - Functional BRCA1, BRCA2, PALB2, - Cannot execute high-fidelity |
| RAD51 execute high-fidelity repair HR repair |
| | | |
| v v |
| [ HIGH-FIDELITY ERROR-FREE REPAIR ] [ FORCED USE OF ERROR-PRONE NHEJ ]|
| | - Unrepaired DSBs, gross |
| v chromosomal translocations |
| [ CELL SURVIVES ] | |
| v |
| [ MITOTIC CATASTROPHE |
| & APOPTOTIC CELL DEATH ] |
+-----------------------------------------------------------------------------+
PARP Trapping vs. Catalytic Inhibition
- While all PARP inhibitors inhibit the catalytic synthesis of poly(ADP-ribose) chains from NAD+, they vary substantially in their potency to trap PARP-DNA complexes on chromatin.
- Trapped PARP-DNA complexes act as physical road blocks to DNA replication forks, creating high-toxicity collapsed replication forks that mandate HR repair.
- PARP Trapping Potency Ranking: Talazoparib >>> Rucaparib = Olaparib > Niraparib.
- Clinical Indications: Maintenance and treatment in BRCA1/2-mutated or HRD-positive ovarian, breast, pancreatic, and castration-resistant prostate cancers.
Test Your Knowledge
A 52-year-old postmenopausal woman with HR-positive, HER2-negative metastatic breast cancer initiates first-line therapy with the nonsteroidal aromatase inhibitor letrozole in combination with the oral CDK4/6 inhibitor ribociclib. During cycle 1 day 15 laboratory monitoring, her absolute neutrophil count (ANC) drops from a baseline of 3,800 cells/µL to 850 cells/µL (Grade 3 neutropenia), with no fever or signs of infection. What molecular mechanism explains the primary therapeutic effect and the observed hematologic toxicity of this regimen?
A
B
C
D
Test Your Knowledge
A 48-year-old woman with advanced high-grade serous ovarian carcinoma harboring a deleterious germline BRCA1 mutation achieves a partial response following 6 cycles of intravenous carboplatin and paclitaxel. The oncologist prescribes maintenance monotherapy with the PARP inhibitor olaparib. What biochemical principle explains why this targeted therapy demonstrates selective cytotoxicity against the patient's malignant cells while sparing healthy somatic tissues?
A
B
C
D
Test Your Knowledge
A 66-year-old patient with relapsed/refractory chronic lymphocytic leukemia (CLL) is initiated on the oral targeted agent venetoclax. To mitigate the risk of life-threatening tumor lysis syndrome (TLS), the clinical oncology pharmacist implements a strict 5-week dose ramp-up schedule (20 mg, 50 mg, 100 mg, 200 mg, to 400 mg daily) accompanied by intensive intravenous hydration, rasburicase prophylaxis, and serial electrolyte monitoring. What is the molecular target and apoptotic mechanism of venetoclax that necessitates this aggressive supportive care strategy?
A
B
C
D
Test Your Knowledge
A 56-year-old patient with newly diagnosed stage IIA (T3N0M0) adenocarcinoma of the colon undergoes complete surgical resection. Immunohistochemical (IHC) analysis of the surgical specimen reveals loss of MLH1 and PMS2 nuclear protein expression, with intact MSH2 and MSH6 expression; molecular testing confirms high microsatellite instability (MSI-H) secondary to MLH1 promoter hypermethylation. When evaluating the appropriateness of adjuvant systemic chemotherapy, what clinical and pharmacogenomic consideration should guide the oncology pharmacist's recommendation?
A
B
C
D